Peer-reviewed literature demonstrates that human urine contains viable, multipotent urine-derived stem cells that can be isolated, cultured, and utilized for research and therapeutic applications.
The concept of utilizing biological waste as a resource dates back centuries, with early practices in traditional medicine repurposing discarded tissues for healing purposes. In recent decades, advances in stem cell biology have revitalized this concept by identifying multipotent stem cells within various waste materials, including urine, adipose tissue, follicular fluid, umbilical cord blood, fetal annexes, menstrual blood, and dental pulp byproducts. These sources offer a minimally invasive, ethically sound, and cost-effective alternative to conventional stem cell harvesting methods. Stem cells derived from waste materials exhibit robust proliferative abilities and multilineage differentiation potential, positioning them as valuable tools for regenerative medicine, tissue engineering, and personalized therapeutic applications. Clinical studies highlight their promise. For example, mesenchymal stem cells from adipose tissue and umbilical cord blood have shown safety and some effectiveness in early trials. These studies report improvements of up to 30-40% in recovery scores for osteoarthritis and ischemic heart disease, as well as a 20-35% decrease in inflammatory markers for autoimmune disorders. Cord blood stem cell transplants have shown 70-90% survival rates in children with blood cancers. This underscores the clinical potential of waste-derived stem cells. However, regulatory issues limit broader use. Agencies like the U.S. Food and Drug Administration and the European Medicines Agency classify many processing methods, especially enzymatic digestion, as "more-than-minimal manipulation." This triggers strict requirements for Good Manufacturing Practice, clinical validation, and safety checks. These rules protect donors, ensure consistency, and check long-term safety. However, they also slow down clinical adoption. This review describes the history and recent advances in recycling biological waste to obtain stem cells, operating within the theoretical framework that positions waste-derived materials as viable sources for regenerative medicine. It highlights how these developments are transforming biomedical research and clinical care.
Urine-derived stem cells (USCs) are multipotent stem cells obtained from human urine, offering a noninvasive and accessible source for both autologous and allogeneic therapies for multiple conditions including acute kidney injury (AKI) due to their renal origin. In our previous study, USCs were tracked in mouse models of AKI including rhabdomyolysis induced by glycerol injection. To track their migration in vivo, 1 × 10<sup>6</sup> luciferase-labeled USCs (luc-USCs) were administered to mice via intraperitoneal injection. In this chapter, we outline a comprehensive protocol for isolating and culturing USCs, as well as transfecting them with luciferase piggyBac transposon plasmids to confer expression of luciferase for tracking. We also detail the use of quantitative bioluminescence tomographic imaging (qBLT) for tracking USC migration and biodistribution, providing accurate spatial and temporal insights. We describe the procedure for generating 3D bioluminescent images and analyzing the data using InVivoAX™ software, offering a precise methodology for studying cell localization in animal models.
<h4>Introduction</h4>Acute-on-chronic liver failure (ACLF) is a highly lethal clinical syndrome with limited effective therapeutic options. Urine-derived stem cells (USCs) represent a non-invasive and readily accessible cell source, but whether USCs obtained from patients with severe liver dysfunction retain therapeutic and immunomodulatory potential remains unclear.<h4>Methods</h4>To address this question, USCs derived from ACLF patients (LF-USCs) were evaluated in a Concanavalin A (Con A)-induced immune-mediated acute liver injury mouse model. Hydrogel-encapsulated LF-USCs were transplanted, and therapeutic efficacy was assessed by survival analysis, serum biochemical parameters, histological examination, and inflammatory cytokine profiling.<h4>Results</h4>Transplantation of hydrogel-encapsulated LF-USCs significantly improved mouse survival, reduced serum transaminase levels, and alleviated hepatocellular necrosis (p < 0.05). At the mechanistic level, LF-USC treatment was associated with decreased systemic inflammatory cytokine levels, attenuation of intrahepatic inflammatory injury, and dynamic modulation of macrophage-associated inflammatory signatures.<h4>Discussion</h4>These findings demonstrate that functionally competent USCs can be successfully obtained from ACLF patients and highlight their potential as a readily accessible autologous cell source for immune modulation and liver tissue repair in immune-mediated acute liver injury.
Everything we examined (3)
This check searched the claim as stated. It did not run a separate search for evidence against it.